Arlington Financial Advisors LLC Acquires 261 Shares of Amgen Inc. (NASDAQ:AMGN)

Arlington Financial Advisors LLC increased its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 1.0% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 25,694 shares of the medical research company’s stock after purchasing an additional 261 shares during the quarter. Amgen accounts for 1.6% of Arlington Financial Advisors LLC’s portfolio, making the stock its 20th biggest holding. Arlington Financial Advisors LLC’s holdings in Amgen were worth $7,305,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of AMGN. Bank of Nova Scotia lifted its holdings in Amgen by 11.4% in the third quarter. Bank of Nova Scotia now owns 54,628 shares of the medical research company’s stock valued at $14,682,000 after acquiring an additional 5,609 shares during the period. CWA Asset Management Group LLC lifted its holdings in Amgen by 26.9% in the third quarter. CWA Asset Management Group LLC now owns 2,334 shares of the medical research company’s stock valued at $627,000 after acquiring an additional 495 shares during the period. Teza Capital Management LLC lifted its holdings in Amgen by 448.3% in the third quarter. Teza Capital Management LLC now owns 5,340 shares of the medical research company’s stock valued at $1,435,000 after acquiring an additional 4,366 shares during the period. Sherbrooke Park Advisers LLC bought a new position in Amgen in the third quarter valued at about $411,000. Finally, Fred Alger Management LLC lifted its holdings in Amgen by 963.8% in the third quarter. Fred Alger Management LLC now owns 95,071 shares of the medical research company’s stock valued at $25,551,000 after acquiring an additional 86,134 shares during the period. 76.50% of the stock is owned by institutional investors.

Amgen Stock Down 0.4 %

AMGN stock traded down $1.24 on Friday, hitting $312.45. 3,518,174 shares of the company’s stock were exchanged, compared to its average volume of 2,437,626. Amgen Inc. has a 12-month low of $218.44 and a 12-month high of $329.72. The firm has a 50 day moving average price of $301.56 and a two-hundred day moving average price of $292.30. The company has a debt-to-equity ratio of 11.96, a quick ratio of 0.98 and a current ratio of 1.42. The stock has a market cap of $167.61 billion, a P/E ratio of 44.64, a price-to-earnings-growth ratio of 2.82 and a beta of 0.60.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Thursday, May 2nd. The medical research company reported $3.96 EPS for the quarter, topping analysts’ consensus estimates of $3.76 by $0.20. Amgen had a return on equity of 156.21% and a net margin of 12.74%. The company had revenue of $7.45 billion during the quarter, compared to analysts’ expectations of $7.45 billion. During the same quarter in the previous year, the firm posted $3.98 EPS. The firm’s revenue was up 22.0% compared to the same quarter last year. As a group, equities research analysts expect that Amgen Inc. will post 19.47 EPS for the current fiscal year.

Insider Activity

In other news, SVP Nancy A. Grygiel sold 2,117 shares of the business’s stock in a transaction dated Friday, May 3rd. The stock was sold at an average price of $313.09, for a total value of $662,811.53. Following the completion of the transaction, the senior vice president now owns 9,883 shares of the company’s stock, valued at approximately $3,094,268.47. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 0.69% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms recently issued reports on AMGN. Royal Bank of Canada increased their target price on Amgen from $328.00 to $332.00 and gave the stock an “outperform” rating in a research report on Friday, June 14th. Mizuho increased their price target on Amgen from $223.00 to $235.00 and gave the company a “neutral” rating in a research note on Thursday, May 9th. StockNews.com raised Amgen from a “hold” rating to a “buy” rating in a research note on Friday, May 3rd. UBS Group increased their price target on Amgen from $284.00 to $307.00 and gave the company a “neutral” rating in a research note on Friday, May 3rd. Finally, Argus increased their price target on Amgen from $300.00 to $340.00 and gave the company a “buy” rating in a research note on Thursday. Ten investment analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. According to MarketBeat.com, Amgen has an average rating of “Moderate Buy” and an average target price of $307.35.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.